962 related articles for article (PubMed ID: 10804042)
41. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Remission Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
Sun J; Yuan Y
Adv Ther; 2016 Mar; 33(3):410-22. PubMed ID: 26905266
[TBL] [Abstract][Full Text] [Related]
42. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
[TBL] [Abstract][Full Text] [Related]
43. Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis.
Leifeld L; Pfützer R; Morgenstern J; Gibson PR; Marakhouski Y; Greinwald R; Mueller R; Kruis W
Aliment Pharmacol Ther; 2011 Nov; 34(9):1115-22. PubMed ID: 21923715
[TBL] [Abstract][Full Text] [Related]
44. The effect of third-party reporting on adoption of evidence-based mesalazine regimens in ulcerative colitis: an observational study.
Kruis W; Leifeld L; Morgenstern J; Pfützer R; Reimers B; Ceplis-Kastner S;
J Crohns Colitis; 2013 May; 7(4):e125-32. PubMed ID: 22951030
[TBL] [Abstract][Full Text] [Related]
45. Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing.
Bokemeyer B; Hommes D; Gill I; Broberg P; Dignass A
J Crohns Colitis; 2012 May; 6(4):476-82. PubMed ID: 22398060
[TBL] [Abstract][Full Text] [Related]
46. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates.
Safdi AV; Cohen RD
Aliment Pharmacol Ther; 2007 Nov; 26(9):1179-86. PubMed ID: 17944732
[TBL] [Abstract][Full Text] [Related]
47. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.
Raedler A; Behrens C; Bias P
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1353-63. PubMed ID: 15606398
[TBL] [Abstract][Full Text] [Related]
48. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group.
Fockens P; Mulder CJ; Tytgat GN; Blok P; Ferwerda J; Meuwissen SG; Tuynman HA; Dekker W; Gasthuis K; van Hees PA
Eur J Gastroenterol Hepatol; 1995 Nov; 7(11):1025-30. PubMed ID: 8680900
[TBL] [Abstract][Full Text] [Related]
49. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
Nakajima H; Munakata A; Yoshida Y
J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
[TBL] [Abstract][Full Text] [Related]
50. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Kamm MA; Sandborn WJ; Gassull M; Schreiber S; Jackowski L; Butler T; Lyne A; Stephenson D; Palmen M; Joseph RE
Gastroenterology; 2007 Jan; 132(1):66-75; quiz 432-3. PubMed ID: 17241860
[TBL] [Abstract][Full Text] [Related]
51. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn's disease in adults.
McKeage K; Goa KL
Drugs; 2002; 62(15):2263-82. PubMed ID: 12381231
[TBL] [Abstract][Full Text] [Related]
52. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.
Brogden RN; Sorkin EM
Drugs; 1989 Oct; 38(4):500-23. PubMed ID: 2684592
[TBL] [Abstract][Full Text] [Related]
53. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
54. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis.
Marakhouski Y; Fixa B; Holomán J; Hulek P; Lukas M; Bátovský M; Rumyantsev VG; Grigoryeva G; Stolte M; Vieth M; Greinwald R;
Aliment Pharmacol Ther; 2005 Jan; 21(2):133-40. PubMed ID: 15679762
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis.
Paridaens K; Fullarton JR; Travis SPL
Curr Med Res Opin; 2021 Nov; 37(11):1891-1900. PubMed ID: 34404286
[TBL] [Abstract][Full Text] [Related]
56. A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis.
Pica R; Cassieri C; Cocco A; Zippi M; Marcheggiano A; De Nitto D; Avallone EV; Crispino P; Occhigrossi G; Paoluzi P
Dig Liver Dis; 2015 Nov; 47(11):933-7. PubMed ID: 26391602
[TBL] [Abstract][Full Text] [Related]
57. Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials.
Zhu Y; Tang RK; Zhao P; Zhu SS; Li YG; Li JB
Eur J Gastroenterol Hepatol; 2012 May; 24(5):487-94. PubMed ID: 22465970
[TBL] [Abstract][Full Text] [Related]
58. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
Sandborn WJ; Kamm MA; Lichtenstein GR; Lyne A; Butler T; Joseph RE
Aliment Pharmacol Ther; 2007 Jul; 26(2):205-15. PubMed ID: 17593066
[TBL] [Abstract][Full Text] [Related]
59. Crohn's Disease with Mesalazine Allergy that Was Difficult to Differentiate from Comorbid Ulcerative Colitis.
Tsuboi R; Matsumoto S; Miyatani H; Mashima H
Intern Med; 2019 Mar; 58(5):649-654. PubMed ID: 30333413
[TBL] [Abstract][Full Text] [Related]
60. Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease.
Steinhart AH; Forbes A; Mills EC; Rodgers-Gray BS; Travis SP
Aliment Pharmacol Ther; 2007 Jun; 25(12):1389-99. PubMed ID: 17539978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
